Drug Interaction Report

Foscarnet Injection and Sultopride: Interaction Details

A pharmacist-reviewed analysis of the Foscarnet Injection and Sultopride interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Foscarnet Injection

Foscavir Foscavir®
+

Sultopride

No brand names on record
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 259 documented Foscarnet Injection interactions, 244 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest)

Interaction Deep Dive

Foscarnet can prolong the QT interval in some patients, which may result in ventricular tachycardia, ventricular fibrillation, and torsades de pointes. Several antipsychotic agents have demonstrated QT prolongation including , haloperidol2, risperidone 3, sertindole 4, sultopride 1, and zotepine 5. Because antipsychotics may also prolong the QT interval and increase the risk of arrhythmias, the concurrent administration of foscarnet and antipsychotics is not recommended 67.

Why it happens (mechanism)

Additive cardiac effects

Common questions

Can I take Foscarnet Injection and Sultopride together?

An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Always confirm with your pharmacist or prescriber before making any change.

How serious is the Foscarnet Injection and Sultopride interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Foscarnet Injection or Sultopride need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (7)

  1. Lande G, Drouin E, Gauthier C, et al: Arrhythmogenic effects of sultopride chlorhydrate: clinical and cellular electrophysiological correlation. Ann Fr Anesth Reanim 1992; 11:629-635.
  2. O'Brien JM, Rockwood RP, & Suh KI: Haloperidol-induced torsade de pointes. Ann Pharmacother 1999; 33(10):1046-1050. PubMed
  3. Duenas-Laita A, Castro-Villamor MA, Martin-Escudero JC, et al: New clinical manifestations of acute risperidone poisoning (letter). Clin Toxicol 1999; 37(7):893-894. PubMed
  4. Agelink MW, Zeit T, Baumann B, et al: In vivo cardiovascular effects of the new atypical neuroleptic sertindole. Int J Psychiatry Clin Pract 2001; 5:33-40. DOI
  5. Sweetman S (Ed): Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Electronic version, MICROMEDEX, Greenwood Village, Colorado, Edition expires 06/2003.
  6. Product Information: Foscavir(R), foscarnet. AstraZeneca, Inc. Alexandria, VA, 1998. DailyMed
  7. Ravin DS & Levenson JW: Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997; 31:867-870. PubMed
Was this write-up helpful?
Foscarnet Injection

Keep reading about Foscarnet Injection

All Foscarnet Injection interactions (259) Foscarnet Injection drug information
Also serious with: Cisapride Dronedarone Levoketoconazole Levomethadyl
Sultopride

Keep reading about Sultopride

All Sultopride interactions (44)
Also serious with: Goserelin Implant Sertraline Dasatinib Oxaliplatin Injection

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.